DRREDDY.NS : Summary for DR REDDYS LABS INR5 - Yahoo Finance

U.S. Markets closed

Dr. Reddy's Laboratories Limited (DRREDDY.NS)

NSE - NSE Delayed Price. Currency in INR
Add to watchlist
2,887.40-15.80 (-0.54%)
At close: 3:29PM IST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close2,903.20
Bid2,887.40 x
Ask0.00 x
Day's Range2,875.00 - 2,924.00
52 Week Range2,798.95 - 3,689.85
Avg. Volume297,253
Market Cap478.13B
PE Ratio (TTM)50.31
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire17 days ago

    Dr. Reddy's Expands Commercial Operations in Europe

    BASEL, Switzerland, February 8, 2017 /PRNewswire/ -- Dr. Reddy's Laboratories Ltd  announced today the expansion of its commercial operations in Europe with the introduction of its portfolio of generics ...

  • American City Business Journals18 days ago

    BioMarin sues to stop generic version of its $90K-a-year drug

    Rare-disease drug developer BioMarin Pharmaceutical Inc. sued an Indian drug maker that plans to make and sell a version of one of BioMarin's top-selling drugs. The San Rafael company (BMRN), led by CEO Jean-Jacques Bienaimé, said in a filing Monday in U.S. District Court in New Jersey that a version of the drug Kuvan by Dr. Reddy's Laboratories Ltd. infringes on six BioMarin patents. The Indian company late last year asked the Food and Drug Administration to approve its powder version of Kuvan, saying that BioMarin's patents are invalid, unenforceable or will not be infringed by manufacturing, use or sale.

  • Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q3
    Zacks19 days ago

    Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q3

    Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 42 cents, down 16% year over year.